Blanket Purchase Agreement 36F79721D0183-36E79725A0015
Award Date
4/25/25
Last Date to Order
4/24/26
Federal Agency
National Acquisition Center
Awardee
Akebia Therapeutics, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian agency, to Otsuka America Pharmaceutical Inc., a large pharmaceutical manufacturer. The $83,342,090.00 BPA is for the supply of the drug Jynarque (tolvaptan) to the Department of Veterans Affairs (VA) healthcare system. Jynarque is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a division of the Department of Veterans Affairs (VA), to Insmed Inc. The contract is for the provision of the pharmaceutical product ARIKAYCE, a liposomal amikacin inhalation medication used to treat nontuberculous mycobacterial lung infections. The BPA has a ceiling value of $49,323.45 and a period of performance ending on June 14, 2025. As a BPA, it will allow the VA to place individual task orders for...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer, to provide critical medications for the treatment of rare diseases such as pulmonary arterial hypertension. The $118.5 million BPA covers the period from August 2024 to August 2025 and allows the VA, Federal Bureau of Prisons, and other federal agencies to procure specialized drug therapies like...
This Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, which is a civilian agency under the U.S. Department of Veterans Affairs (VA). The single-award BPA has a ceiling value of $7,000,000 and was awarded to Aurinia Pharma US Inc., a for-profit pharmaceutical company, to provide the drug Lupkynis. The BPA aims to procure Lupkynis, an immunosuppressant medication recently approved by the FDA for the treatment of...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Amryt Pharmaceuticals Inc., a foreign-owned, for-profit organization, on November 5, 2022. The potential value of the BPA is $1,000,000. No set-aside was used. The BPA is for a single award and permits ordering of Mycapssa, Juxtapid, and Myalept through March 14, 2024. Mycapssa, Juxtapid, and Myalept are pharmaceutical products used to treat certain rare diseases. The Department of...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, which is a civilian agency under the Department of Veterans Affairs (VA), to Marius Pharmaceuticals LLC, a self-certified small disadvantaged business. The BPA has a ceiling value of $1,406.70 and a period of performance through March 2026. The purpose of this BPA is to facilitate the procurement of the pharmaceutical product KYZATREX by VA medical centers nationwide. Marius Pharmaceuticals, which holds a...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Marius Pharmaceuticals LLC, a self-certified small disadvantaged business organized as a limited liability company. The BPA has a ceiling value of $10,000,000 and a period of performance through January 31, 2024. The primary purpose of this BPA is to facilitate the procurement of a specific pharmaceutical product called KYZATREX by the Department of Veterans Affairs (VA) and its...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to United Therapeutics Corporation, a self-certified small disadvantaged business and for-profit manufacturer of pharmaceutical goods. The BPA has a ceiling value of $207,127,385 and a performance period extending through April 2026. It allows the VA to procure specialized pharmaceutical products from United Therapeutics' portfolio, including Orenitram, Remodulin, Tyvaso,...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Fera Pharmaceuticals, LLC, a woman-owned small business. The BPA, valued at up to $255,000, is for the procurement of Phospholine Iodide, a pharmaceutical drug. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and allows the VA and other agencies to efficiently and compliantly acquire the needed pharmaceutical product from Fera...